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Autophagy as a new therapeutic target in Duchenne
muscular dystrophy
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C De Palma1, F Morisi2,8, S Cheli1,8, S Pambianco1, V Cappello3,4, M Vezzoli5, P Rovere-Querini5, M Moggio6, M Ripolone6,
M Francolini3, M Sandri*,7 and E Clementi*,1,2
A resolutive therapy for Duchene muscular dystrophy, a severe degenerative disease of the skeletal muscle, is still lacking.
Because autophagy has been shown to be crucial in clearing dysfunctional organelles and in preventing tissue damage, we
investigated its pathogenic role and its suitability as a target for new therapeutic interventions in Duchenne muscular dystrophy
(DMD). Here we demonstrate that autophagy is severely impaired in muscles from patients affected by DMD and mdx mice, a
model of the disease, with accumulation of damaged organelles. The defect in autophagy was accompanied by persistent
activation via phosphorylation of Akt, mammalian target of rapamycin (mTOR) and of the autophagy-inhibiting pathways
dependent on them, including the translation-initiation factor 4E-binding protein 1 and the ribosomal protein S6, and
downregulation of the autophagy-inducing genes LC3, Atg12, Gabarapl1 and Bnip3. The defective autophagy was rescued in
mdx mice by long-term exposure to a low-protein diet. The treatment led to normalisation of Akt and mTOR signalling; it also
reduced significantly muscle inflammation, fibrosis and myofibre damage, leading to recovery of muscle function. This study
highlights novel pathogenic aspects of DMD and suggests autophagy as a new effective therapeutic target. The treatment we
propose can be safely applied and immediately tested for efficacy in humans.
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Muscular dystrophies are a group of genetic, hereditary
muscle diseases characterised by defects in muscle proteins.
These defects result in progressive skeletal muscle damage
accompanied by myofibre necrosis and chronic local inflam-
mation, leading to substitution of myofibres by connective and
adipose tissue.1 In Duchenne muscular dystrophy (DMD), the
most severe form of these diseases, the continuous and
progressive skeletal muscle damage leads to complete
paralysis and death of patients, usually by respiratory and/or
cardiac failure.2
The therapeutic protocols currently in use, based on
corticosteroid administration, provide some delay in the
progression of the disease, but they are associated with
severe side effects.3,4 Therapies that substitute corticoster-
oids or at least may act as corticosteroid-sparing drugs are
thus being actively pursued, and biological mechanisms
relevant to skeletal muscle homoeostasis are explored, in
order to identify new targets.
Autophagy is emerging as an important process that
limits muscle damage.5,6 Inhibition/alteration of autophagy
contributes to myofibre degeneration leading to accumulation
of abnormal organelles.7,8 Mutations that inactivate Jumpy,
a phosphatase that counteracts the activation of VPS34 for
autophagosome formation and reduces autophagy, are asso-
ciated with a centronuclear myopathy.9 This observation sug-
gests that unbalanced autophagy is pathogenic in muscle
degeneration. Likewise, hyperactivation of Akt as a consequence
ofmuscle-specific deletion of themammalian target of rapamycin
(mTOR) leads to inhibition of autophagy and to a muscle
phenotype resembling theoneobserved inmuscular dystrophy.10
The validity of autophagy modulation as a therapeutic
strategy has been shown in a mouse model of Ulrich
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myopathy characterised by defective autophagy and accu-
mulation of dysfunctional organelles.11,12 Forced reactivation
of autophagy in these animals yielded a beneficial therapeutic
response.11
Indirect evidence indicates a possible role of deficient
autophagy also in DMD pathogenesis. Higher levels of
activation and phosphorylation of Akt are observed inmuscles
and primary myoblasts of the mdx mouse model of dystro-
phy.13,14 In agreement with this observation, the progressive
muscular dystrophic phenotype observed in mdx mice is
accompanied by progressively enhanced Akt activation
especially at peak necrotic and hypertrophic phases of
disease.14 Such a phenotype has also been described
in patients affected by DMD.14 Akt is the most potent inhibitor
of autophagy in skeletal muscle, blocking formation of
autophagosomes and lysosomal-dependent degradation of
their content,15,16 thereby suggesting a defective auto-
phagic process. Moreover, histo-pathological hallmarks of
DMD, namely protein aggregation, presence of swollen
and damaged mitochondria, as well as distension of sarco-
plasmic reticulum, are often observed when autophagy is
impaired.17,18
The molecular pathways and the role of autophagy in DMD
had not yet been investigated. We have now investigated the
autophagic machinery in themdxmousemodel of DMD and in
muscle tissues from DMD-affected patients. We found by
in vivo and ex vivo analyses that autophagy is defective in both
the human and mouse muscular dystrophy and that such
defect contributes to the pathogenesis of the disease.
Furthermore, we show that pharmacological reactivation of
autophagy restoresmuscle structure and function. Our results
identify autophagy as an important homoeostatic mechanism
deranged in dystrophic muscles and indicate that novel
therapeutic approaches aimed at reactivating autophagy are
a valuable strategy to reduce muscle damage in DMD.
Results
Autophagy is reduced in mdx mice. To explore the status
of autophagy in the dystrophic muscle, we compared key
markers of autophagy in muscles from 4-month-old mdx and
wild-type (WT) mice. We examined tibialis anterior (TA) and
diaphragm muscles, because they are good examples of
muscles relying on glycolytic and oxidative metabolism,11
respectively, and closely mimic typical features of human
muscular dystrophy, including myofibres with central nuclei
and clustering of inflammatory cells.13
As shown in Figure 1a, the levels of the lipidated form of the
microtubule-associated protein-1 light chain 3 (LC3 II), which
is generated during autophagosome formation and reflects
active autophagy,19 were significantly lower in muscles from
mdx than in those of WT animals. The levels of p62, a protein
known to be incorporated into autophagosomes and efficiently
degraded,20 were instead increased.
We found enhanced levels of Akt in both TA and diaphragm
muscles from mdx mice as already described.13,14 Of
importance, we also found that phosphorylation of Akt on
Ser473 was significantly increased as it was the phosphoryla-
tion of key downstream effectors of mTOR, namely the
ribosomal protein S6 and the eukaryotic translation-initiation
factor 4E-binding protein 1 (4E-BP1) (Figure 1b). Phosphor-
ylation of these proteins leads to their activation, which in
muscle may lead to inhibition of autophagy.21
Akt phosphorylation maintains mTOR in its active form and
prevents FoxO3 translocation from the cytoplasm to the
nucleus with ensuing transcriptional inhibition of genes
essential to autophagosome formation.12 In agreement with
this, we found lower mRNA expression of autophagy-related
genes directly regulated by FoxO3, that is, LC3, Atg12,
Gabarapl1 and Bnip3 in mdx mouse muscles (Figure 3e),
indicating that FoxO3 downstream targets are impaired in
Figure 1 Autophagy is defective inmdxmice. (a) Muscle homogenates frommdx andWTmice (60 mg per lane) were immunoblotted with antibodies against LC3 and p62.
LC3 lipidation (LC3 II) in TA and in diaphragm muscles of mdx mice is reduced when compared with that of WT mice. The mdx mice also show accumulation of p62.
Densitometric quantification of the LC3 II/I ratio and of p62, normalised against actin, is also shown. (b) In muscle homogenates (60 mg per lane), phosphorylation levels of Akt,
S6 and 4E-BP1 are enhanced inmdxmice when compared with those of WT. We used the same protein extracts as in panel a. Densitometric analyses show the ratio between
phosphorylated and corresponding total protein. In both panels, western blots are representative, and quantifications correspond to 15 animals per group. The asterisks
indicate statistical significance versus WT (*Po0.05 and **Po0.01). Error bars represent S.E.M.
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mdxmice and providing a molecular correlate to the observed
deficiency in autophagy.
Reduced autophagy in mdx mice is due to defective
pro-autophagic signalling. Reduced LC3 II levels may
depend on direct inhibition of autophagic flux; alter-
natively, they may be due to progressive exhaustion of LC3
II-containing vesicles following a hyperactivation of autop-
hagy. To discriminate between these two possibilities, we
used chloroquine, a lysosomal inhibitor that blocks the
degradation of autophagosomes and their content, including
of LC3 and p62.22 Mice were treated with chloroquine,
administered at the dose of 50mg/kg body weight per day,
for 7 days. This treatment led to significant increases in the
levels of LC3 bands and p62 in both TA and diaphragm
muscles of WT animals; such increases were not observed in
the corresponding samples of mdx mice (Figures 2a and b).
These data indicate that the reduced LC3 II levels observed
in mdx mouse muscles are not the consequence of vesicles
exhaustion secondary to a hyperactive autophagic process.
We next subjected mice to short-term starvation (6 and 15 h
of fasting), a treatment that activates autophagic signalling in
different organs, including in muscles.23 Starvation enhanced
LC3 II levels with increased LC3 II/I ratio in TA and diaphragm
muscles of WT mice; the levels of p62 were instead reduced,
consistent with its enhanced degradation (Figures 3a and b
and Supplementary Figure S1a). No effects of starvation on
LC3 II and p62 levels were instead observed in mdx mouse
muscles (Figures 3a and b and Supplementary Figure S1a).
Chloroquine enhanced the LC3 II/I ratio further and induced
accumulation of p62 in muscles from WT animals, whereas it
was completely ineffective inmdxmousemuscles (Figures 3a
and b).
In agreement with these results, starvation decreased
significantly phospho-Akt and phospho-4E-BP1 levels in WT
animals (Figures 3c and d and Supplementary Figure S1b),
where it also upregulated LC3B, Atg12, Bnip3 and Gabarapl1
mRNA levels (Figure 3e), consistent with Akt and mTOR
signalling inhibition and with autophagy induction.
No changes in protein phosphorylation or mRNA expres-
sion were instead observed in mdx mouse muscles after
starvation, indicating a deficiency in pro-autophagic signalling
(Figures 3c and e).
We then analysed the ultrastructure of TA of WT and mdx
mice in basal conditions (Figures 4a and c). We detected
defects neither in the architecture of the contractile apparatus
nor in the mitochondrial pool of WT muscles (Figure 4a and
inset); in mdx mice, although the contractile apparatus
seemed mostly unaffected (Figure 4c), we observed an
expansion of the cisternae of the endoplasmic reticulum in
subsarcolemmal regions, where they occasionally form
swollen stacks (Supplementary Figures S2a and b); this
feature was even more prominent in starved mdx mice
(Figure 4d). Moreover, in tissues from mdx mice, infiltrating
Figure 2 Chloroquine treatment of WT and mdx mice. (a and b) The western blots show the levels of LC3 and p62 in TA (a) and diaphragm (b) muscles of mdx and WT
mice treated (þ ) or not ( ) with chloroquine diphosphate at 50mg/kg body weigh daily for 7 days. The absence of choloroquine effects inmdx (but not WT) mice indicate that
the defect in LC3 II expression is due to an actual deficit of autophagy and not the consequence of autophagic vesicle exhaustion secondary to hyperactivation of autophagy.
Western blotting are representative, and quantifications correspond to 15 animals per group. Asterisks indicate statistical significance versus untreated WT (**Po0.01 and
***Po0.001). Error bars represent S.E.M.
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cells and collagen fibres were seen among myofibres
(Supplementary Figures S2c and d). In muscles derived from
WT-starved animals (Figure 4b), we observed the presence of
autophagosomes associated with intracellular organelles (mostly
mitochondria, Figure 4b inset); in contrast, in muscles derived
from starved mdx mice, although damaged organelles were
observed (mainly mitochondria of the subsarcolemmal pool),
these were never associated with autophagosomes (Figure 4d).
Figure 3 Autophagy induction is impaired in mdx mice. (a and b) Western blots showing LC3 and p62 levels in TA (a) and diaphragm (b) muscles (60mg per lane) of fed
and 15 h-starved (15 h) WT andmdxmice, treated (þ ) or not ( ) with chloroquine 50mg/kg body weight daily for 7 days. Densitometric quantification of LC3 II/I ratio and of
p62 levels, normalised against actin, shows induction of autophagy only in WTmice after 15 h of starvation. (c and d) Western blots, using the same protein extracts of panels a
and b, reveal reduction of Akt and 4E-BP1 phosphorylation in diaphragm and TA muscles of 15 h-starved WT mice. The mdx muscles display no changes in the
phosphorylation levels of both proteins. (e) Quantitative RT-PCR analysis of LC3b, Atg12, Gaparapl1 and Bnip3 mRNA levels in diaphragm and TA muscles of fed and
15 h-starved WT andmdxmice. The genes downstream of FoxO3 are upregulated in WT mice after starvation, but not in themdxmice. Western blots are representative, and
quantifications correspond to 15 animals per group. Asterisks indicate statistical significance versus WT-fed mice (*Po0.05, **Po0.01 and ***Po0.001); crosses indicate
statistical significance versus WT-starved mice (þ þ þPo0.001). Error bars represent S.E.M.
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Autophagy reactivation improves the dystrophic pheno-
type ofmdxmice. A specific dietary regimen, characterised
by low amino-acid intake, but with the same caloric value of
standard food was shown to ameliorate the dystrophic
feature of Col6 / mice by enhancing in a chronic and
physiological manner skeletal muscle autophagic machin-
ery.11,12 We investigated whether a 3-month treatment
with such a low-protein diet (LPD) reactivated autophagy in
mdx mice and the impact of this effect on the dystrophic
phenotype. LPD treatment enhanced expression of LC3 II
and reduced that of p62 in TA and diaphragm not only
in WT but also inmdxmice, with dephosphorylation, and thus
inactivation, of Akt and 4E-BP1 (Figures 5a and b).
Consistently, we observed enhanced RNA levels of autho-
pagic genes downstream to FoxO3 (Figure 5c and data not
shown). Such an effect was not observed in mice treated with
a control, standard diet (SD). Thus a long-term LPD was able
to reactivate autophagy in mdx mice.
We then investigated the therapeutic efficacy of the LPD
treatment. In LPD-treatedmdxmice, theWhole Body Tension
measurement, which determines the total phasic forward
pulling tension exerted by the fore and hind limb muscles,24,25
was significantly improved as compared with SD-treated
animals (Figure 5c). Histological analyses by the haematox-
ylin and eosin (H&E) staining revealed a degenerated muscle
status in SD-treated mdx mice; in contrast, muscle architec-
ture was nearly normal in LPD-treated mice, with a signifi-
cantly lower number of necrotic myofibres (Figure 5d).
The beneficial effect of the diet was also apparent when the
myofibre cross-sectional area (CSA) was investigated. The
heterogeneity in myofibre CSA observed in SD-treated mdx
mice, in which values ranged between 250 and 3000 mm2, with
the largest diameters being a sign of degeneration
(pathological hypertrophy) (Figure 5e), was normalised in
LPD-treated animals, with significantly more homogeneous
frequency histograms and CSA values not significantly
different from those observed in WT animals.
The percentage of apoptotic nuclei, measured using the
TdT-mediated dUTP-biotin nick end labelling (TUNEL)
method, was significantly lower in LPD-treated compared
with SD-treated mdx mice, both in TA and diaphragm
(Figure 6c). This finding suggests that the treatment with
LPD reduced also the programmed death of myofibres.
Interestingly, LPD treatment in mdx mice increased also the
number of centronucleated myofibres (Figure 5d), indicating a
benefit on muscle regeneration. Consistently, fibrosis and
collagen accumulation was reduced in LPD-treated animals
as assessed by the Masson’s Trichrome staining (Figure 6a).
Muscles of LPD-treatedmdxmice showed an uptake of the
Evans blue dye (EBD) injected i.v., which was significantly
reduced with respect to that in SD-treated mice (Figure 6b).
Because EBD stains damaged myofibres,26 this finding
indicates that the treatment reduced the fragility of sarcolem-
mas in mdx mice.26
It is noteworthy that long-lasting induction of autophagy in
WT led to minor muscle alterations, as previously demon-
strated by others,11 including the increase of apoptotic
degeneration of the myofibres, shown by an increased
number of TUNEL-positive nuclei (Figure 6c). This was
expected because previous studies have already demon-
strated that excessive autophagy induction is detrimental
for muscle homoeostasis in healthy conditions, further high-
lighting the importance of a balanced autophagic flux.
Autophagy is defective in human DMD patients. We
assessed whether the defect in autophagy observed in mdx
Figure 4 Autophagy induction in WT andmdxmice. (a) electron micrographs of TA muscles fromWT mice. No defects in the architecture of the contractile apparatus or in
the mitochondrial pool are observed in WT-fed mice (scale bars 1 mm, 200 nm in the inset). (b) The 15 h-starved TA muscles of WT mice (b and insets) show alteration of
mitochondrial pool and an increase of autophagosomes, identified as double-membrane structures associated with degenerating organelles (inset) (scale bars 1mm, 200 nm
in the insets). (c) Electron micrographs of TA muscles from fed mdx mice. No autophagosomes are detectable, and the defect in autophagy is accompanied by expansion of
endoplasmic reticulum cisternae expansion (scale bar 1mm). (d) Themdx-starved TA muscles present an increased level of altered organelles, in particular of mitochondria in
the subsarcolemmal pool, that are not related with lytic organelles (d and inset) (scale bars 1mm, 200 nm in the inset). Images are representative of reproducible results in 10
animals per group
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mice applied also to the human disease. We analysed
muscle biopsies from five DMD-affected patients and four
relative controls. All tissues from DMD patients showed
significantly lower levels of LC3 II and significant accumula-
tion of p62 with respect to tissues from the controls
(Figure 7a). In addition, they showed enhanced phosphor-
ylation of Akt and of 4E-BP1 (Figure 7b), indicating that the
pathway affected in DMD patients is identical to the one
observed in mdx mice leading to a multi step inhibition of
autophagy.
Discussion
In this study, we report that autophagy is defective in DMD, that
defects in autophagy contribute significantly to the pathology of
DMD, and that pharmacological strategies that reactivate auto-
phagy have beneficial effects that can be exploited in thera-
peutic perspective. Moreover, we characterise the signalling
mechanisms involved in autophagic deficiency in DMD.
The defect in autophagy was demonstrated by biochemical
and ultrastructural analyses. We found a significant reduction
Figure 5 Prolonged autophagy induction by LPD ameliorates dystrophy in mdx mice. WT and mdx mice were fed with LPD or SD for 3 months. (a and b) The
representative western blots of homogenates (60 mg per lane) from TA (a) and diaphragm (b) muscles show that LPD enhances LC3 II and p62 expression, whereas reducing
phosphorylation of Akt and 4E-BP1 both in WT andmdxmice. (c)Quantitative RT-PCR analysis of LC3b, Atg12, Gaparapl1 and Bnip3mRNA levels in TA fed with SD or LPD.
(d) In vivo analysis of muscle force was measured as the amount of whole body pulling force, calculated as the force relative to body weight in WT andmdx. WBT10 represents
the media of 10 FPTs, measured as grams of tension, divided by body weight. WBT5 represents the media of top-five FPTs divided by body weight. LPD improved muscle
force in mdx mice. (e) TA and diaphragm muscles were stained with H&E; centronucleated and necrotic myofibres were counted. LPD reduces necrotic myofibres and
increases centronucleated myofibres. Scale bar 110mm. (f) Distribution of CSA values of 700 myofibres of TA muscle of WT andmdx treated with LPD or SD. LPD normalises
the CSA distribution in mdx. Images and western blots in the various panels are representative, and quantifications correspond to 15 animals per group. Asterisks indicate
statistical significance versus WT (*Po0.05, **Po0.01 and ***Po0.001); crosses indicate statistical significance versus mdx normally fed (þPo0.05; þ þPo0.01 and
þ þ þPo0.001). Error bars represent S.E.M.
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in LC3 II, the active, lipidated form of LC3, in muscles from
both DMD patients andmdxmice. The reduction in LC3 II was
accompanied by clear signs of impaired autophagy at the
ultrastructural level, with enhanced presence of damaged
organelles. The reduction in the autophagic flux was further
confirmed by the increase in p62 levels. The impairment in
autophagy in the mouse model could not be rescued by up to
15h of fasting, a treatment known to stimulate autophagic
signalling in other conditions.23 Restoration of autophagy,
leading to increased levels of LC3 II and reduced levels of p62,
required instead a long-term (3 months) treatment with a
potent autophagy-reactivating treatment (LPD). These find-
ings suggest that the defect in autophagy is due to an overall
deficiency in the autophagic machinery rather than to a simple
inhibition of the signalling pathways that stimulate autophagy.
When we investigated the autophagic signalling pathways
and their alteration in muscular dystrophy, we found that
inhibition of autophagy depended on Akt activation, as shown
by its persistent phosphorylation reversible upon autophagy
reactivation. Although we cannot exclude the intervention of
multiple mechanisms, such as lysosomal defects, we found
that downstream of Akt both the mTOR and FoxO3 pathways
Figure 6 Prolonged autophagy induction by LPD ameliorates dystrophy in mdx mice. WT and mdx mice were fed with LPD or SD for 3 months. (a) TA and diaphragm
muscles representative sections, stained with the Masson’s Trichrome procedure reveal reduced accumulation of collagen and fibrosis in LPD-treatedmdx versus SD-treated
mdx. Scale bar 110mm. The graph shows the quantification carried out in five sections per animal. (b) Fibre membrane damage, evaluated by assessing EBD uptake,
quantified by the Image 1.63 (Scion Corporation) software as % of Evans blue-positive cells. The representative images show that LPD reduce EBD uptake inmdxmice. Scale
bar 110mm. The graph shows the quantification carried out in five sections per animal. (c) Quantification of TUNEL-positive nuclei in TA muscles of WT and mdx mice; LPD
reduces the number of TUNEL-positive nuclei compared withmdx. Quantification (number of TUNEL-positive nuclei normalised per mm2) was carried out with the Image 1.63
(Scion Corporation) software. Images in the various panels are representative, and quantifications correspond to 10 animals per group. Asterisks indicate statistical
significance versus WT (*Po0.05, **Po0.01 and ***Po0.001). Error bars represent S.E.M.
Figure 7 Autophagy is defective in human DMD patients. (a) Analysis of the LC3 ratio and p62 levels in human muscle biopsies from four control subjects and five DMD
patients. p62 expression is normalised on GAPDH. (b) Western blots for pAKT and p4E-BP1 in protein lysates of human biopsies using the same protein extract of panel a.
DMD patients show higher Akt and 4E-BP1 phosphorylation compared with controls. Western blots are representative, and quantifications correspond to results in biopsies
from five DMD patients and four controls. Asterisks indicate statistical significance versus controls (*Po0.05 and **Po0.01). Error bars represent S.E.M.
Autophagy reactivation is therapeutic in mdx mice
C De Palma et al
7
Cell Death and Disease
were involved as shown by the persistent phosphorylation of
4E-BP1, and the downregulation of Atg12, Bnip3 and
Gabarapl1 also reversed when autophagy was reactivated.
Although the role of FoxO3 signalling in autophagy in
skeletal muscle has already been assessed and investigated
fully,15,16 our observation of a significant involvement
of mTOR signalling in autophagy is an unexpected finding.
To date, the role of mTOR in muscle autophagy, investigated
in conditions different from DMD, that is, muscle atrophy and
fasting conditions, was reported to be minor.15,16,27 Indeed,
inhibition of mTOR by rapamycin or its downregulation by
RNA-mediated silencing in those settings was insufficient to
induce autophagosome formation15,16,27 and only slightly
increased protein breakdown.16 The observation of a relevant
role of mTOR in mdx mice suggests that autophagy in DMD
has characteristics and molecular constrains unique with
respect to autophagy in other pathophysiological condition of
skeletal muscle. A possible explanation of this specificity
resides in the specific features of DMD, and the role of mTOR
in it. Dystrophic muscle is characterised by repeated cycles of
degeneration/regeneration, with the presence of regenerating
and hypertrophic fibres generated as a compensatory
mechanism due at least in part to hyperactivation of Akt and
mTOR.13,14 Although important, this functional compensation
also leads to inhibition of autophagy.
The role of autophagy in DMD pathophysiology and its
relevance as a therapeutic target was investigated in a long-
term treatment ofmdxmice with LPD. We evaluated carefully
several unrelated markers of muscle function, damage and
regeneration, and inflammatory responses. These markers
were investigated using multiple different approaches in mdx
mice after 3 months of treatment with the low protein or SDs.
Our results clearly show that LPD treatment has therapeutic
efficacy and ameliorates the dystrophic phenotype of mdx
mice. Indeed, we observed a significant recovery of muscle
function, as shown by the improvement of whole body tension,
accompanied by reducedmuscle fibrosis, decreased collagen
deposition into the muscle, reduced apoptosis of the
myofibres and reduced accumulation of damaged organelles.
Furthermore, the treatment preserved the regenerating ability
of muscle, assessed as an increased number of centronu-
cleated myofibres and uniform CSA distribution. These latter
results suggest in particular that LPD maintains the number
and function of myogenic precursor cells. Autophagy has
indeed been shown to have roles as promoter of stem cell
maintenance and in a variety of cell differentiation processes,
including in cellular reprogramming.28 Our results are
consistent with a similar role of autophagy also in myogenic
precursor cells.
We cannot exclude that the beneficial effects of LPD
treatment depend on mechanisms other than autophagy, for
example, by increased muscle homoeostasis.29 Altogether,
however, our findings suggest that a proper autophagic flux
contributes significantly to rescue the dystrophic phenotype
and that stimulation of autophagy represents a new pharma-
cological strategy in DMD.
Our results contribute to explain recent findings about an
amelioration of the dystrophic phenotype using the mTOR
inhibitor.30 Rapamycin, however, may not be an appropriate
long-term treatment for human DMD, because it completely
blocks muscle growth of regenerating myofibres31,32 and has
intrinsic toxicity. Our results explain also why enhancement of
autophagy by the AMP-activated protein kinase stimulating
agent 5-aminoimidazole-4-carboxamide 1-b-D-ribofurano-
side, tested specifically in the diaphragm of mdx mice, leads
to muscle functional and structural improvement.33 Although
this compound may be developed further for clinical applica-
tion in DMD, the efficacy in humans of the treatment we report
here can be tested immediately and safely.
Several other compounds acting on the pathways different
from autophagy are now being explored in novel therapeutic
strategies for DMD. Among these exon skipping and stem
cell approaches appear a significant step forward to
resolutive therapy, although not yet developed to a sufficient
level of efficacy, as the results of the last clinical trials
indicate.2,34–36 Classical pharmacological approaches based
on drugs targeting inflammation, fibrosis, epigenetic DNA
modifications and redox modifications are also being tested,
with favourable perspectives.37–44 In this scenario, the
therapeutic approach that we propose appears of significant
value: although we do not expect an approach targeting only
autophagy to be resolutive, it can be safely used in
combination with cell and gene therapies and with the other
drugs currently being explored for treatment of DMD. Thus, it
can achieve a synergic effect and possibly lead to drug-
sparing regimes. In particular, in the case of steroids, a drug-
sparing regime may be of particular value limiting their
adverse reactions, which appear to be severe in approxi-
mately a third of the treated patients.45
In conclusion, this study demonstrates the existence of a
defect in autophagy in human and mouse muscular dystro-
phy, and that a treatment restoring autophagy ameliorates the
dystrophic phenotype. Inhibition of muscle damage and
inflammation, as well as maintenance of muscle regenerative
capacity, appears to account for the therapeutic effect of this
treatment.
Materials and Methods
Animals and treatments. C57BL/6 WT mice (C57Bl10SnJ strain) were
purchased from Charles River (Wilmington, MA, USA), mdx mice (C57Bl10-mdx
strain) from Jackson (Bar Harbor, ME, USA) and treated in accordance with the
European Community guidelines and with the approval of the Institutional
Ethical Committee.
The mice were housed in an environmentally controlled room (23 1C, 12 h
light–dark cycle) and provided food and water ad libitum. For specific experiments,
groups of mice (15 animals per group) were fed with either SD or LPD (see Table 1
for its composition). For starvation experiments, chow was removed in the morning
and mice (15 animals per group) were maintained for 6 or 15 h with no food but free
access to water. In the experiments with chloroquine, mdx mice (15 animals per
group) were subjected to intraperitoneal injection with chloroquine diphosphate
(50mg/kg body weight; Sigma-Aldrich, Milano, Italy) every 24 h for 7 days.
Human muscle sample. Normal and DMD muscle samples were
obtained from the ‘Bank of DNA, cell lines and nerve-muscle cardiac tissue’ of
the Neurological Unit of the Foundation IRCCS Ca’ Granda- Ospedale
Maggiore Policlinico of Milan, which is part of the Telethon Genetic Biobank
network of Italy.
In vivo functional tests. The Whole Body Tension procedure was used to
determine the ability of mice to exert tension in a forward pulling manoeuvre that is
elicited by stroking the tail. The Whole Body Tension reflects the maximal acute
phasic force the mouse can achieve to escape a potentially harmful event. The
tails of the mice (SD or LPD-fed) were connected to a Grass FT03 transducer
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(Astro-Med Industrial Park, West Warwick, RI, USA) with a 4.0 silk thread (one end
of the thread being tied to the tail and the other end to the transducer). Each mouse
was placed into a small tube constructed of a metal screen with a grid spacing of
2mm. The mice entered the apparatus and exerted a small resting tension on the
transducer. Forward pulling movements were elicited by a standardised stroke of
the tail with serrated forceps, and the corresponding forward pulling tensions were
recorded using a Grass Polyview recording system. Between 20 and 30 strokes
of the tail, forward pulling tensions were generally recorded during each session.
The Whole Body Tension was determined by dividing the average of the top 5 or
top 10 forward pulling tensions, respectively, by the body weight.
Histology and immunohistochemistry. The animals were killed by
cervical dislocation, and TA or diaphragm muscles were dissected and
immediately frozen in liquid N2-cooled isopentane. For histological analyses,
serial muscle sections were obtained and stained in H&E following standard
procedures.46 The number of necrotic and centronucleated fibres was counted
and analysed using the public domain software MBF_ImageJ for Microscopy
(http://www.macbiophotonics.ca/index.htm).
To measure CSA of individual myofibres, muscle sections were stained with an
anti-Laminin A (L1293; Sigma-Aldrich) antibody. Laminin, a major component of the
basal lamina, was detected using an appropriate secondary antibody, and nuclei
were visualised with the DNA dye 40,6-diamidino-2-phenylindole (DAPI). Masson’s
Trichrome staining was used for identifying collagen inside the muscle tissue,
following standard protocols.40
Morphometry. Morphometric analyses were performed on sections collected
from similar regions of each TA and diaphragm muscles. Two images were
captured from each section and Image 1.63 (Scion Corporation, Frederick, MD,
USA) was used to determine the CSA of 700–1.000 myofibres per section.47
EBD injection. As a measure for membrane permeability, the vital dye EBD
was used. In all, 50ml/g body weight of a 5mg/ml solution of EBD (Sigma-Aldrich)
prepared in physiological saline was injected i.v. through the tail vein. Mice were
killed 18 h after EBD injection.
Apoptosis assay. Apopotsis was assessed by the TUNEL method on 10-mm
cryosections using an in situ apoptosis detection kit (DeadEnd Fluorometric TUNEL
System; Promega, Milano, Italy), according to the manufacturer’s protocol. Sections
were counterstained with DAPI and mounted with Vectashield (Vector Laboratories,
Burlingame, CA, USA). The data were expressed as TUNEL index, calculated by
counting the number of TUNEL-positive nuclei divided by the DAPI-positive nuclei.
The TUNEL index was calculated from four random and non-overlapping fields.
Fluorescent and phase-contrast image acquisition and manip-
ulation. Fluorescent and phase-contrast images were taken on microscopes
(Leica DMI4000 B automated inverted microscope; lenses: HCX PL FLUOTAR
 10/0.30, HI PLAN I  40/0.59 and HCX PL FLUOTAR  100/1.30). Images
were acquired using a DFC490 digital colour camera (Leica Microscopy Systems,
Heerbrugg, Switzerland) and the acquisition software LAS AF (Leica Microscopy
Systems). Images were assembled in panels using Photoshop 7.0 (Abobe System
Software, Dublin, Ireland).
Electron microscopy. For transmission electron microscopy (TEM) analysis,
entire diaphragms and TA from WT and mdx mice were dissected after the killing
and fixed for 1 h in a solution containing 4% paraformaldehyde and 0.5% glutar-
aldehyde in 0.1M cacodylate buffer, pH 7.4, immobilised on a Sylgard coated Petri
dish to prevent muscular contraction. The muscles were rinsed in the same buffer
and further dissected into smaller blocks (1mm3) that were subsequently processed
for TEM as described elsewhere.48 Briefly, the samples were postfixed with osmium
tetroxide (2% in cacodylate buffer), rinsed, en bloc stained with 1% uranyl acetate
in 20% ethanol, dehydrated and embedded in epoxy resin (Epon 812; Electron
Microscopy Science, Hatfield, PA, USA) that was baked for 48 h at 67 1C. Thin
sections were obtained with an ultramicrotome (Reichert Ultracut E and UC7; Leica
Microsystems, Vienna, Austria), stained with uranyl acetate and lead citrate, and
finally examined with a Philips CM10 TEM (FEI, Eindhoven, Germany).
Protein isolation and western blotting. Tissue samples from TA and
diaphragm muscles were homogenised in a lysis buffer containing 20mM Tris HCl
(pH 7.4), 10mM EGTA, 150mM NaCl, 1% Triton X-100, 10% glycerol supplemented
with a cocktail of protease and phosphatase inhibitors (Sigma, St. Louis, MO, USA).
Samples were centrifuged at 1.000 g for 10min at 4 1C to discard nuclei and
cellular debris. Protein concentration was determined by the bicinchoninic acid assay
(Pierce, Thermo Fisher Scientific, Rockford, IL, USA). Homogenates were separated
by SDS-PAGE and proteins were transferred to nitrocellulose membranes (Amersham
Pharmacia, Piscataway, NJ, USA). The membranes were probed using the following
antibodies anti: phospho- AMPKa (Thr172) (2531), AMPKa (2532), 4E-BP1 (9644),
phospho-4E-BP1 (Thr37 and Thr46) (2855), Akt (9272), phospho-Akt (Ser473) (9271),
S6 (2317) and phospho-S6 (Ser240 and Ser244) (2215), all obtained from Cell
Signaling Technology (Billerica, MA, USA). Antibodies to b-Actin (A5441), LC3
(L7543) and p62 (P0067) were from Sigma.
After immunostaining with the appropriate secondary horse radish peroxidase-
conjugated goat anti-rabbit or anti-mouse antibodies (from Cell Signaling, Beverly,
CA, USA, and Bio-Rad, Milano, Italy, respectively), bands were revealed using the
Amersham ECL detection system (GE Healthcare, Fairfield, CT, USA) and
quantified by densitometry using the public domain software MBF_ImageJ for
Microscopy (http://www.macbiophotonics.ca/index.htm).
Real-time PCR. Tissue samples were homogenised, and RNA was extracted
using the TRIzol protocol (Invitrogen, Carlsbad, CA, USA). After solubilisation in
RNase-free water, first-strand cDNA was generated from 1 mg of total RNA using
the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA). Specific
sets of primer pairs, described in Table 2, were designed to hybridise to unique
regions of the appropriate gene sequence. Real-time PCR was performed using
the SYBR Green Supermix (Bio-Rad) on a Roche LightCycler 480 Instrument
(Roche Diagnostics, Rotkreuz, Switzerland). All reactions were run as triplicates.
Samples were analysed using the Roche LightCycler 480 Software (release 1.5.0)
and the second derivative maximum method. The fold increase or decrease was
determined relative to a control after normalising to the internal standard 36b4.
Statistical analyses. Values were expressed as means±S.E.M.
The statistical significance of the differences between means was assessed by
independent Student’s t-test or by one-way ANOVA followed by the Bonferroni
post-test to determine which groups were significantly different from the others.
A probability of o5% (Po0.05) was considered to be significant.





Proteins (%) 22.5 5.0
Fat (%) 5.4 10.0
Fibres (%) 3.6 4.3
Carbohydrates (%) 66.5 76.2
Minerals and vitamins (%) 2.5 4.5
Energy (kcal/g) 4.03 4.15
The diets were designed as described previously.11
Table 2 Primers used for quantitative real-time RT-PCR analyses
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